Anemia Drugs Sales Raise Questions
Anemia Drugs Safety Raised Questions. Three popular anemia drugs may have generated billions of dollars in revenue for two companies but they’ve proven to be dangerous and a drain on the federal health care system and patients’ wallets. An investigation launched by The Washington Post reveals that Amgen and Johnson & Johnson … [Read more...] about Anemia Drugs Sales Raise Questions
Procrit, Epogen Recalled, Vials May Contain Glass Flakes
Vials May Contain Glass Flakes. Some lots of Epogen and Procrit (Epoetin alfa) are being recalled today over concerns that some vials may be contaminated with extremely thin, barely visible gas flakes. A complete list of the affected lots is available here. Procrit and Epogen are erythropoiesis-stimulating agents (ESAs). ESAs are … [Read more...] about Procrit, Epogen Recalled, Vials May Contain Glass Flakes
New Labeling for Procrit, Aranesp and Epogen
Procrit, Aranesp and Epogen New Label. FDA Forces New Labeling, Federal regulators have decided that the anemia drugs Aranesp, Epogen and Procrit need to have additional safety-related changes to their labels. The changes mandated by the Food & Drug Administration (FDA) would restrict the use of the drugs in some … [Read more...] about New Labeling for Procrit, Aranesp and Epogen
Tests Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Study Says Genetic Tests May Predict if Procrit. Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher recently reported that there may be a way to predict which cancer patients are at risk for this devastating side effect. Procrit, Aranesp and … [Read more...] about Tests Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Procrit, Epogen and Aranesp Marketing Investigation
Procrit, Epogen Marketing Investigation. Two members of Congress are looking into to allegations that the marketing of Procrit, Aranesp and Epogen encouraged overuse of the anemia drugs, placing some patients in danger. Reps. John Dingell and Bart Stupak, both Michigan Democrats, sent letters to Amgen and Johnson & Johnson on … [Read more...] about Procrit, Epogen and Aranesp Marketing Investigation
Procrit, Aranesp, Epogen Restricted by FDA
Procrit, Aranesp, Epogen. Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug Administration (FDA). Late last week, the FDA announced a new black box warning for Procrit, Aranesp and Epogen regarding their association with shortened … [Read more...] about Procrit, Aranesp, Epogen Restricted by FDA
Aranesp Black Box Warning
Aranesp, Epogen, Procrit Black Box Warning. Aranesp, Epogen and Procrit, drugs used to treat anemia in patients undergoing chemotherapy, will soon bear new black box warnings that they may shorten survival time in patients with certain types of tumors. Amgen's Aranesp and Epogen, and Johnson & Johnson's Procrit, have … [Read more...] about Aranesp Black Box Warning
Epogen Aranesp and Procrit Fatal Blood Clots Risk
Epogen, Aranesp and Procrit. Epogen, Aranesp and Procrit, anemia drugs used to treat cancer patients, have been linked to a higher risk of a potentially fatal type of blood clot. According to a review published in the February 27 issue of the Journal of the American Medical Association, anemia drugs—medications designed to fight … [Read more...] about Epogen Aranesp and Procrit Fatal Blood Clots Risk
Aranesp, Epogen and Procrit Policy Justified
Aranesp, Epogen, Procrit Policy Justified, More trouble for Aranesp, Epogen and Procrit. Senior Medicare official Dr. Barry Straube said evidence—including two studies—is mounting in the case for cutting the use of controversial anemia drugs sold by Amgen Inc. and Johnson & Johnson. Medicare cut payments for the use … [Read more...] about Aranesp, Epogen and Procrit Policy Justified
Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Aranesp, Epogen, Procrit May Cause Leukemia. Aranesp, Epogen and Procrit have been linked to yet another deadly side effect. New research suggests that the anemia drugs, known as erythropoiesis-stimulating agents (ESAs), might play a role in the development of a form of leukemia when they are used to treat people with a … [Read more...] about Aranesp, Epogen and Procrit Linked to Leukemia in Some Patients
Controversy over Aranesp, Epogen and Procrit to Be Addressed by FDA Panel
Controversy over Aranesp, Epogen and Procrit. Aranesp, Epogen and Procrit, drugs given to anemia patients suffering end-stage kidney failure, will be taken up by a Food & Drug Administration (FDA) advisory panel tomorrow. Earlier this year, the FDA added a black box warning to the products’ labels recommending that … [Read more...] about Controversy over Aranesp, Epogen and Procrit to Be Addressed by FDA Panel
Doubts on Epogen Drug
Drives Doubts on Epogen Drug. Epogen combats anemia by raising red-blood counts in kidney patients. But Medicare has been under fire for allowing doses that exceed FDA-recommended limits and that, in clinical trials, have been shown to pose risks of fatal heart attacks and strokes. Earlier this month, the FDA issued a black-box … [Read more...] about Doubts on Epogen Drug
